# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
-PH-762 is Phio's lead product candidate -Screening on the next cohort is on-goingMARLBOROUGH, Mass., May 15, 2024 (GLOBE N...
HC Wainwright & Co. analyst Vernon Bernardino reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $4 price tar...
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.47) per share. This is a 85.08 percent increase over losses of $(3.1...